CIPHER PHARMACEUTICALS INC (CPH.CA) Fundamental Analysis & Valuation

TSX:CPH • CA17253X1050

Current stock price

16.56 CAD
-0.01 (-0.06%)
Last:

This CPH.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. CPH.CA Profitability Analysis

1.1 Basic Checks

  • CPH had positive earnings in the past year.
  • CPH had a positive operating cash flow in the past year.
  • CPH had positive earnings in 4 of the past 5 years.
  • Of the past 5 years CPH 4 years had a positive operating cash flow.
CPH.CA Yearly Net Income VS EBIT VS OCF VS FCFCPH.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 11.77%, CPH belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 15.23%, CPH belongs to the top of the industry, outperforming 87.88% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 7.23%, CPH belongs to the top of the industry, outperforming 87.88% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for CPH is in line with the industry average of 9.22%.
Industry RankSector Rank
ROA 11.77%
ROE 15.23%
ROIC 7.23%
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
CPH.CA Yearly ROA, ROE, ROICCPH.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

1.3 Margins

  • With an excellent Profit Margin value of 34.68%, CPH belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • In the last couple of years the Profit Margin of CPH has grown nicely.
  • With an excellent Operating Margin value of 25.51%, CPH belongs to the best of the industry, outperforming 87.88% of the companies in the same industry.
  • In the last couple of years the Operating Margin of CPH has declined.
  • CPH has a Gross Margin of 74.32%. This is amongst the best in the industry. CPH outperforms 93.94% of its industry peers.
  • In the last couple of years the Gross Margin of CPH has declined.
Industry RankSector Rank
OM 25.51%
PM (TTM) 34.68%
GM 74.32%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
CPH.CA Yearly Profit, Operating, Gross MarginsCPH.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CPH.CA Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CPH is still creating some value.
  • There is no outstanding debt for CPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CPH.CA Yearly Shares OutstandingCPH.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CPH.CA Yearly Total Debt VS Total AssetsCPH.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 6.97 indicates that CPH is not in any danger for bankruptcy at the moment.
  • CPH has a better Altman-Z score (6.97) than 93.94% of its industry peers.
  • The Debt to FCF ratio of CPH is 0.45, which is an excellent value as it means it would take CPH, only 0.45 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.45, CPH belongs to the top of the industry, outperforming 93.94% of the companies in the same industry.
  • A Debt/Equity ratio of 0.12 indicates that CPH is not too dependend on debt financing.
  • With a decent Debt to Equity ratio value of 0.12, CPH is doing good in the industry, outperforming 69.70% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 0.45
Altman-Z 6.97
ROIC/WACC0.87
WACC8.34%
CPH.CA Yearly LT Debt VS Equity VS FCFCPH.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 1.30 indicates that CPH should not have too much problems paying its short term obligations.
  • CPH's Current ratio of 1.30 is on the low side compared to the rest of the industry. CPH is outperformed by 69.70% of its industry peers.
  • CPH has a Quick Ratio of 1.30. This is a bad value and indicates that CPH is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CPH has a Quick ratio of 0.98. This is comparable to the rest of the industry: CPH outperforms 42.42% of its industry peers.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 0.98
CPH.CA Yearly Current Assets VS Current LiabilitesCPH.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CPH.CA Growth Analysis

3.1 Past

  • CPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 126.09%, which is quite impressive.
  • CPH shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 43.65% yearly.
EPS 1Y (TTM)126.09%
EPS 3YN/A
EPS 5Y43.65%
EPS Q2Q%292.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.35%

3.2 Future

  • The Earnings Per Share is expected to decrease by -11.86% on average over the next years. This is quite bad
  • The Revenue is expected to grow by 17.62% on average over the next years. This is quite good.
EPS Next Y-42.22%
EPS Next 2Y-11.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.09%
Revenue Next 2Y17.62%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
CPH.CA Yearly Revenue VS EstimatesCPH.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
CPH.CA Yearly EPS VS EstimatesCPH.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 1 -1

More info and screens

Find the best growth stocksShow best growing peers

5

4. CPH.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 11.58 indicates a reasonable valuation of CPH.
  • 81.82% of the companies in the same industry are more expensive than CPH, based on the Price/Earnings ratio.
  • CPH's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.54.
  • A Price/Forward Earnings ratio of 20.10 indicates a rather expensive valuation of CPH.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of CPH indicates a somewhat cheap valuation: CPH is cheaper than 69.70% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of CPH to the average of the S&P500 Index (22.70), we can say CPH is valued inline with the index average.
Industry RankSector Rank
PE 11.58
Fwd PE 20.1
CPH.CA Price Earnings VS Forward Price EarningsCPH.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as CPH.
  • Based on the Price/Free Cash Flow ratio, CPH is valued a bit cheaper than the industry average as 78.79% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 10.21
EV/EBITDA 15.75
CPH.CA Per share dataCPH.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • CPH has a very decent profitability rating, which may justify a higher PE ratio.
  • A cheap valuation may be justified as CPH's earnings are expected to decrease with -11.86% in the coming years.
PEG (NY)N/A
PEG (5Y)0.27
EPS Next 2Y-11.86%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CPH.CA Dividend Analysis

5.1 Amount

  • No dividends for CPH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CPH.CA Fundamentals: All Metrics, Ratios and Statistics

CIPHER PHARMACEUTICALS INC

TSX:CPH (3/23/2026, 7:00:00 PM)

16.56

-0.01 (-0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-12
Earnings (Next)05-06
Inst Owners1.32%
Inst Owner ChangeN/A
Ins Owners3.63%
Ins Owner ChangeN/A
Market Cap418.64M
Revenue(TTM)N/A
Net Income(TTM)17.36M
Analysts77.5
Price Target19.58 (18.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.24%
Min EPS beat(2)36.14%
Max EPS beat(2)66.34%
EPS beat(4)2
Avg EPS beat(4)14.52%
Min EPS beat(4)-37.21%
Max EPS beat(4)66.34%
EPS beat(8)5
Avg EPS beat(8)34.73%
EPS beat(12)9
Avg EPS beat(12)113.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.76%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)-0.16%
Revenue beat(12)3
Avg Revenue beat(12)1.53%
Revenue beat(16)3
Avg Revenue beat(16)-1.19%
PT rev (1m)0%
PT rev (3m)6.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.79%
Revenue NY rev (1m)0.21%
Revenue NY rev (3m)0.21%
Valuation
Industry RankSector Rank
PE 11.58
Fwd PE 20.1
P/S 6.1
P/FCF 10.21
P/OCF 10.18
P/B 2.68
P/tB 13.37
EV/EBITDA 15.75
EPS(TTM)1.43
EY8.64%
EPS(NY)0.82
Fwd EY4.97%
FCF(TTM)1.62
FCFY9.8%
OCF(TTM)1.63
OCFY9.82%
SpS2.71
BVpS6.18
TBVpS1.24
PEG (NY)N/A
PEG (5Y)0.27
Graham Number14.1
Profitability
Industry RankSector Rank
ROA 11.77%
ROE 15.23%
ROCE 10.05%
ROIC 7.23%
ROICexc 7.75%
ROICexgc 33.36%
OM 25.51%
PM (TTM) 34.68%
GM 74.32%
FCFM 59.76%
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score7
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 0.45
Debt/EBITDA 0.67
Cap/Depr 1.2%
Cap/Sales 0.17%
Interest Coverage 250
Cash Conversion 152.24%
Profit Quality 172.34%
Current Ratio 1.3
Quick Ratio 0.98
Altman-Z 6.97
F-Score7
WACC8.34%
ROIC/WACC0.87
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)126.09%
EPS 3YN/A
EPS 5Y43.65%
EPS Q2Q%292.31%
EPS Next Y-42.22%
EPS Next 2Y-11.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.35%
Revenue Next Year3.09%
Revenue Next 2Y17.62%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.19%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year143.14%
EBIT Next 3Y45.59%
EBIT Next 5YN/A
FCF growth 1Y98.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.32%
OCF growth 3Y12.28%
OCF growth 5Y19.77%

CIPHER PHARMACEUTICALS INC / CPH.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CPH.CA.


What is the valuation status for CPH stock?

ChartMill assigns a valuation rating of 5 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.


What is the profitability of CPH stock?

CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 7 / 10.


What are the PE and PB ratios of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?

The Price/Earnings (PE) ratio for CIPHER PHARMACEUTICALS INC (CPH.CA) is 11.58 and the Price/Book (PB) ratio is 2.68.


How financially healthy is CIPHER PHARMACEUTICALS INC?

The financial health rating of CIPHER PHARMACEUTICALS INC (CPH.CA) is 6 / 10.